Akademiliv

Sahlgrenska akademins nyheter

På Svenska
University of Gothenburg Logotype
  • News
  • Notices
  • Calendar
  • Grants
  • About Akademiliv

Alcohol drinking cut in half with diabetes medication

8 June, 2023 Leave a Comment

NEW STUDY. The medication semaglutide, which is currently used in the treatment of type 2 diabetes and obesity, might also be an effective medication for alcohol dependence. In a study from the University of Gothenburg, the drug reduced alcohol relapse drinking and alcohol intake in rats by more than half.

Semaglutide is sold under brand names such as Ozempic. Since this medication was also approved for the treatment of obesity, demand has increased, which has resulted in difficulties in procuring the drug in recent times. There is anecdotal evidence of patients with obesity or diabetes saying that their craving for alcohol has lessened since they started taking the drug.

Today, individuals with alcohol dependence are treated with a combination of various psychosocial methods and medications. Four approved medications are available. Since alcohol dependence is a disease with many causes, the efficacy of these medications varies, and so it is important that we develop additional treatment medications.

Reduced relapses

Semaglutide is a long-acting substance that only needs to be taken once a week. This is the first medication to act on the GLP-1 receptor that can be taken in tablet form.

The results of the study are published in the scientific journal eBioMedicine. In the study, alcohol-dependent rats were treated with semaglutide, which significantly reduced their alcohol consumption and even reduced the drinking of alcohol in conjunction with relapses. Relapses comprise a major problem for individuals with alcohol dependence, as an individual who has abstained from alcohol for a period relapses and drink more than before the withdrawal.

In the study, the treated rats cut their alcohol intake in half compared to animals that did not receive treatment. One interesting finding in the study was that semaglutide reduced alcohol intake equally in both male and female rats.

Animals and humans

The study reports a strikingly good effect, although clinical studies will be required before the medication can be used for alcohol dependence, and such studies take time. Moving forward, the medication may be of most benefit to patients suffering from both overweight and alcohol dependence. According to the researchers it is likely that these results will carry over to humans, as results from other studies on alcohol dependency medications made with the same research model have shown similar effect in humans as in rats.

Elisabet Jerlhag Holm. Photo: Johan Wingborg.

“There are, of course, differences in conducting studies on animals and humans, and these must always be taken into account. However, in this case, there is a previous study on humans in which an older version of the diabetes medications that act on GLP-1 was found to reduce alcohol intake in overweight individuals with alcohol dependence,” says Elisabet Jerlhag, professor of pharmacology at Sahlgrenska Academy at the University of Gothenburg.

Mechanisms in the brain

The current study also examined why the medication reduces alcohol drinking. The results indicate that reduced alcohol-induced reward could be a contributing factor. In the study, semaglutide affected the brain’s reward system in mice, to be more exact the nucleus accumbens area of the brain, which is part of the limbic system.

Cajsa Aranäs. Photo: Elin Lindström.

“Alcohol activates the brain’s reward system, resulting in the release of dopamine, something that is seen in both humans and animals. This process is blocked by the medication in mice, and with our interpretation, this could cause a reduction in the alcohol-induced reward,” says Cajsa Aranäs, doctoral student at Sahlgrenska Academy at the University of Gothenburg, who is responsible for much of the work behind the study presented here.

Title: Semaglutide Reduces Alcohol Intake and Relapse-like Drinking in Male and Female Rats

BY: ELIN LINDSTRÖM

By: Elin Lindström
Tagged With: institutionen för neurovetenskap och fysiologi, Ny studie, vetenskaplig publicering

Leave a Comment Cancel reply

Your email address will not be published. Required fields are marked *

Add your own events in the Akademiliv Calendar

Master’s and bachelor’s thesis fair in health and technology

Registration for supervisors
Last day to register: October 4th.

Information from Sahlgrenska Academy Research Support Office

[UPDATED SEPTEMBER 20]
The Sahlgrenska Academy Research Support Office provides an overview of upcoming and current calls, nominations and events in an information letter. This letter is updated approximately four times per semester.

’20 minutes for researchers’ is back – see full autumn program

During 20 minutes over Zoom, the Biomedical Library gives tips on tools and services that can facilitate your research everyday life.

We are building at Medicinareberget

You will now find comprehensive information on construction projects that affect the Sahlgrenska Academy in the Staff Portal.

More news

The autumn ALF announcements 2023 have been published

25 September, 2023

GRANTS. The call for ALF positions for registered doctors has now been published on the ALF portal. The application period is October 19 to …  

Lower risk of haematological cancer after bariatric surgery

21 September, 2023

NEW STUDY. Obesity surgery is associated with a 40% lower risk of haematological cancer. This has been shown in a study at the University of …  

Education administrator – and extreme cyclist

21 September, 2023

LIFESTYLE. The heat of the Mojave Desert nearly ended his solo bike ride from Los Angeles to New York during the summer. The US trip is just the …  

Obesity particularly hard on people with bipolar disorders

20 September, 2023

NEW STUDY. The obesity pandemic is particularly hard on people with bipolar disorders. This has been shown in a study conducted at the University …  

New Head of the Faculty Office: Annelie Tobin

18 September, 2023

MANAGEMENT ASSIGNMENT. With twenty years of experience, primarily within education and internationalization at Sahlgrenska Academy, Annelie Tobin …  

The pandemic a tough time also for pharmacies

15 September, 2023

NEW STUDY. Customers showing up even when they were sick, not agreeing with the restrictions, and many new tasks for staff. These are factors …  

Joint research to develop municipal healthcare and social services

14 September, 2023

INTER-ACTION. A recent letter of intent signed between the University of Gothenburg and the City of Gothenburg opens up greater opportunities to …  

Axel Wolf new Director of the Centre for Person-centred Care

14 September, 2023

ASSIGNMENT. Axel Wolf, Professor at the Institute of Health and Care Sciences, has now become the new Centre Director of the University of …  

Helena Filipsson Nyström visited the Swedish Parliament – to draw attention to a neglected women’s disease

12 September, 2023

INTER-ACTION. Almost half a million Swedes have hypothyroidism, an underactive thyroid gland. Four out of five affected are women and the number …  

Two announcements right now for DDLS Fellows at the University of Gothenburg

12 September, 2023

POSITIONS. The University of Gothenburg has two currently advertised positions within SciLifeLab & Wallenberg National Program for …  

More news...

Sahlgrenska Academy

© University of Gothenburg
PO-Box 100, S-405 30 Gothenburg, Sweden
Phone: 00 46 31 786 0000

About the website

Elin Lindström is editor for Akademiliv.
Please feel free to send your ideas and comments to akademiliv@gu.se

Sign up for the Akademiliv newsletter:

Send you tips to Akademiliv

Do you have a suggestion for news, grants, seminars or an education?
Send an email to Elin Lindström Claessen